Fluid-attenuated inversion recovery （FLAIR） vascular hyperintensity （FVH） is used to assess leptomeningeal collateral circulation, but clinical outcomes of patients with FVH can be very different. The aim of the p...Fluid-attenuated inversion recovery （FLAIR） vascular hyperintensity （FVH） is used to assess leptomeningeal collateral circulation, but clinical outcomes of patients with FVH can be very different. The aim of the present study was to assess a FVH score and explore its relationship with clinical outcomes. Patients with acute ischemic stroke due to middle cerebral artery M1 occlusion underwent magnetic resonance imaging and were followed up at 10 days （National Institutes of Health Stroke Scale） and 90 days （modified Rankin Scale） to determine short-term clinical outcomes. Effective collateral circulation indirectly improved recovery of neurological function and short-term clinical outcome by extending the size of the pial penumbra and reducing infarct lesions. FVH score showed no correlation with 90-day functional clinical outcome and was not sufficient as an independent predictor of short-term clinical outcome.展开更多
BACKGROUND Most studies on Guhong injection have involved a single center with a small sample size,and the level of clinical evidence is low.AIM To assess the safety and efficacy of Guhong injection for mild ischemic ...BACKGROUND Most studies on Guhong injection have involved a single center with a small sample size,and the level of clinical evidence is low.AIM To assess the safety and efficacy of Guhong injection for mild ischemic stroke(IS).METHODS A total of 399 IS patients treated at six hospitals from August 2018 to August 2019 were retrospectively analyzed.The patients were given Guhong injection(experimental group)or Butylphthalide injection(control group).Changes in National Institutes of Health Stroke Scale(NIHSS)and modified Rankin Scale(mRS)scores were observed before treatment and at 1,2,and 3 wk after treatment in each group.The efficacy and safety of Guhong injection for IS were assessed.Other medications taken by the patients were confounding factors for efficacy assessment.These factors were controlled by propensity score matching,and the results were further analyzed based on the matching.RESULTS The marked response rates at three follow-up visits were 64.64%,74.7%,and 66.7%in the experimental group,and 48.26%,45.4%,and 22.2%in the control group.The marked response rates increased significantly in the experimental group compared with the control group(P<0.05).The overall response rate at the first visit(days 7±2)did not differ significantly between the two groups,but differed significantly at the second(days 14±2)and third visits(days 21±3)(P<0.05).The proportion of patients without any symptoms in the experimental group was significant different at the first visit(P<0.05),but not significantly different at the second visit.The two groups showed no significant difference in the baseline distribution of mRS scores.At the first and second visits,the change in mRS scores was-2 and-1 in the experimental and control groups,respectively,which were significantly different(P<0.05).After propensity score matching,the overall response rate and marked response rate were 97.29%and 100%in the experimental group(P>0.05)and 64.0%and 47.7%in the control group(P<0.05)at the first visit,respectively.The decreased NIHSS scores in the two groups were significant different(P<0.05).The overall response rate and marked response rate differed significantly between the two groups at the second visit(P<0.05).There was no significant difference in the incidence of adverse events between the two groups.No severe adverse events occurred in either group.CONCLUSION Guhong injection is safe and more effective than Butylphthalide injection for treatment of IS.展开更多
BACKGROUND Acute ischemic stroke(AIS)is one of the major causes of the continuous increasing rate of global mortality due to the lack of timely diagnosis,prognosis,and management.This study provides a primitive platfo...BACKGROUND Acute ischemic stroke(AIS)is one of the major causes of the continuous increasing rate of global mortality due to the lack of timely diagnosis,prognosis,and management.This study provides a primitive platform for non-invasive and cost-effective diagnosis and prognosis of patients with AIS using circulating cellfree mitochondrial DNA(cf-mtDNA)quantification and validation.AIM To evaluate the role of cf-mtDNA as s non-invasive,and affordable tool for realtime monitoring and prognosticating AIS patients at disease onset and during treatment.METHODS This study enrolled 88 participants including 44 patients with AIS and 44 healthy controls with almost similar mean age group at stroke onset,and at 24 h and 72 h of treatment.Peripheral blood samples were collected from each study participant and plasma was separated using centrifugation.The cf-mtDNA concentration was quantified using nanodrop reading and validated through real-time quantitative polymerase chain reaction(RT-qPCR)of NADH-ubiquinone oxidoreductase chain 1(ND1)relative transcript expression levels.RESULTS Comparative analysis of cf-mtDNA concentration in patients at disease onset showed significantly increased levels compared to control individuals for both nanodrop reading,as well as ND1 relative expression levels(P<0.0001).Intergroup analysis of cf-mtDNA concentration using nanodrop showed significantly reduced levels in patients at 72 h of treatment compared to onset(P<0.01).However,RT-qPCR analysis showed a significant reduction at 24 h and 72 h of treatment compared to the disease onset(P<0.001).The sensitivity and specificity were relatively higher for RT-qPCR than nanodrop-based cfmtDNA quantification.Correlation analysis of both cf-mtDNA concentration as well as ND1 relative expression with National Institute of Health Stroke Scale score at baseline showed a positive trend.CONCLUSION In summary,quantitative estimation of highly pure cf-mtDNA provides a simple,highly sensitive and specific,non-invasive,and affordable approach for real-time monitoring and prognosticating AIS patients at onset and during treatment.展开更多
Cerebral blood perfusion and cerebrovascular lesions are important factors that can affect the therapeutic efficacy of thrombolysis.At present,the majority of studies focus on assessing the accuracy of lesion location...Cerebral blood perfusion and cerebrovascular lesions are important factors that can affect the therapeutic efficacy of thrombolysis.At present,the majority of studies focus on assessing the accuracy of lesion location using imaging methods before treatment,with less attention to predictions of outcomes after thrombolysis.Thus,in the present study,we assessed the efficacy of combined computed tomography（CT） perfusion and CT angiography in predicting clinical outcomes after thrombolysis in ischemic stroke patients.The study included 52 patients who received both CT perfusion and CT angiography.Patients were grouped based on the following criteria to compare clinical outcomes：（1） thrombolytic and non-thrombolytic patients,（2） thrombolytic patients with CT angiography showing the presence or absence of a vascular stenosis,（3） thrombolytic patients with CT perfusion showing the presence or absence of hemodynamic mismatch,and（4） different CT angiography and CT perfusion results.Short-term outcome was assessed by the 24-hour National Institution of Health Stroke Scale score change.Long-term outcome was assessed by the 3-month modified Rankin Scale score.Of 52 ischemic stroke patients,29 were treated with thrombolysis and exhibited improved short-term outcomes compared with those without thrombolysis treatment（23 patients）.Patients with both vascular stenosis and blood flow mismatch（13 patients） exhibited the best short-term outcome,while there was no correlation of long-term outcome with CT angiography or CT perfusion findings.These data suggest that combined CT perfusion and CT angiography are useful for predicting short-term outcome,but not long-term outcome,after thrombolysis.展开更多
目的探讨美国国立卫生研究院卒中量表(NIHSS)评分<6分的合并大血管闭塞的急性缺血性卒中(AIS-LVO)患者行血管内治疗(EVT)的预后影响因素。方法回顾性选取2021年1月至2023年1月在浙江省台州医院接受EVT的42例NIHSS评分<6分的AIS-LV...目的探讨美国国立卫生研究院卒中量表(NIHSS)评分<6分的合并大血管闭塞的急性缺血性卒中(AIS-LVO)患者行血管内治疗(EVT)的预后影响因素。方法回顾性选取2021年1月至2023年1月在浙江省台州医院接受EVT的42例NIHSS评分<6分的AIS-LVO患者为研究对象。根据术后90 d改良Rankin量表(mRS)评分评估患者预后,比较预后良好组与预后不良组患者的临床资料,采用多因素logistic回归分析预后影响因素。结果所有患者均成功实现血管再通(100.0%),术中均未发生血栓逃逸、血管损伤、夹层、出血事件;术后发生24 h症状性颅内出血1例(2.4%),恶性脑水肿1例(2.4%)。随访90 d mRS评分显示预后良好33例,预后不良9例(未发生死亡病例)。预后良好组与预后不良组在年龄、术前舒张压、穿刺至再灌注时间等方面比较,差异均有统计学意义(均P<0.05)。穿刺至再灌注时间是影响NIHSS评分<6分的AIS-LVO患者行EVT预后的独立危险因素(OR=1.026,P=0.029)。结论NIHSS评分<6分的AIS-LVO患者行EVT可能是安全有效的,缩短穿刺至再灌注时间可能改善患者预后。展开更多
目的通过对美国国立卫生研究院卒中量表（NIHSS）评分变化率的分析试图为脑梗死临床结局评价方法的选择提供一种新的思路与方法。方法本项研究采取前瞻性设计对来自10个临床研究中心急性期脑梗死住院患者的数据内容进行分析,筛选出入院...目的通过对美国国立卫生研究院卒中量表（NIHSS）评分变化率的分析试图为脑梗死临床结局评价方法的选择提供一种新的思路与方法。方法本项研究采取前瞻性设计对来自10个临床研究中心急性期脑梗死住院患者的数据内容进行分析,筛选出入院当天NIHSS评分、发病90 d NIHSS评分和BI数据资料完整患者953例,将患者按入院时NIHSS评分分为3级：轻度（〈7分）、中度（7分-15分）、重度（〉15分）,以BI作为功能残疾的疗效判定＂金标准＂,发病90 d BI≥95分为预后良好、BI〈95分为预后不良的分界点将BI转换为二分类变量（残疾与否）,应用ROC曲线了解NIHSS的变化率对脑梗死患者发病90天功能残疾的判断价值。结果本研究发现NIHSS变化率预测脑梗死患者发病90 d功能残疾的AUC曲线下面积均〉0.70,轻度患者为0.76、中度患者为0.85,重度患者为0.97,与AUC曲线下面积=0.50进行比较,差异有统计学意义（P≤0.001）。预测脑梗死患者良好功能结局的最佳NIHSS变化率的截断值在轻度、中度、重度神经功能缺损的患者分别为70.8%、74.7%、84.9%;其灵敏度在三者分别为63.0%、81.8%、100.0%,特异度分别为78.1%、75.4%、94.3%。结论 NIHSS的变化率对脑梗死患者发病90 d功能残疾具有较好的预测能力,且这种预测能力随着神经功能缺损程度的增加而增大。展开更多
基金supported by the National Natural Science Foundation of China,No.81371521
文摘Fluid-attenuated inversion recovery （FLAIR） vascular hyperintensity （FVH） is used to assess leptomeningeal collateral circulation, but clinical outcomes of patients with FVH can be very different. The aim of the present study was to assess a FVH score and explore its relationship with clinical outcomes. Patients with acute ischemic stroke due to middle cerebral artery M1 occlusion underwent magnetic resonance imaging and were followed up at 10 days （National Institutes of Health Stroke Scale） and 90 days （modified Rankin Scale） to determine short-term clinical outcomes. Effective collateral circulation indirectly improved recovery of neurological function and short-term clinical outcome by extending the size of the pial penumbra and reducing infarct lesions. FVH score showed no correlation with 90-day functional clinical outcome and was not sufficient as an independent predictor of short-term clinical outcome.
文摘BACKGROUND Most studies on Guhong injection have involved a single center with a small sample size,and the level of clinical evidence is low.AIM To assess the safety and efficacy of Guhong injection for mild ischemic stroke(IS).METHODS A total of 399 IS patients treated at six hospitals from August 2018 to August 2019 were retrospectively analyzed.The patients were given Guhong injection(experimental group)or Butylphthalide injection(control group).Changes in National Institutes of Health Stroke Scale(NIHSS)and modified Rankin Scale(mRS)scores were observed before treatment and at 1,2,and 3 wk after treatment in each group.The efficacy and safety of Guhong injection for IS were assessed.Other medications taken by the patients were confounding factors for efficacy assessment.These factors were controlled by propensity score matching,and the results were further analyzed based on the matching.RESULTS The marked response rates at three follow-up visits were 64.64%,74.7%,and 66.7%in the experimental group,and 48.26%,45.4%,and 22.2%in the control group.The marked response rates increased significantly in the experimental group compared with the control group(P<0.05).The overall response rate at the first visit(days 7±2)did not differ significantly between the two groups,but differed significantly at the second(days 14±2)and third visits(days 21±3)(P<0.05).The proportion of patients without any symptoms in the experimental group was significant different at the first visit(P<0.05),but not significantly different at the second visit.The two groups showed no significant difference in the baseline distribution of mRS scores.At the first and second visits,the change in mRS scores was-2 and-1 in the experimental and control groups,respectively,which were significantly different(P<0.05).After propensity score matching,the overall response rate and marked response rate were 97.29%and 100%in the experimental group(P>0.05)and 64.0%and 47.7%in the control group(P<0.05)at the first visit,respectively.The decreased NIHSS scores in the two groups were significant different(P<0.05).The overall response rate and marked response rate differed significantly between the two groups at the second visit(P<0.05).There was no significant difference in the incidence of adverse events between the two groups.No severe adverse events occurred in either group.CONCLUSION Guhong injection is safe and more effective than Butylphthalide injection for treatment of IS.
文摘BACKGROUND Acute ischemic stroke(AIS)is one of the major causes of the continuous increasing rate of global mortality due to the lack of timely diagnosis,prognosis,and management.This study provides a primitive platform for non-invasive and cost-effective diagnosis and prognosis of patients with AIS using circulating cellfree mitochondrial DNA(cf-mtDNA)quantification and validation.AIM To evaluate the role of cf-mtDNA as s non-invasive,and affordable tool for realtime monitoring and prognosticating AIS patients at disease onset and during treatment.METHODS This study enrolled 88 participants including 44 patients with AIS and 44 healthy controls with almost similar mean age group at stroke onset,and at 24 h and 72 h of treatment.Peripheral blood samples were collected from each study participant and plasma was separated using centrifugation.The cf-mtDNA concentration was quantified using nanodrop reading and validated through real-time quantitative polymerase chain reaction(RT-qPCR)of NADH-ubiquinone oxidoreductase chain 1(ND1)relative transcript expression levels.RESULTS Comparative analysis of cf-mtDNA concentration in patients at disease onset showed significantly increased levels compared to control individuals for both nanodrop reading,as well as ND1 relative expression levels(P<0.0001).Intergroup analysis of cf-mtDNA concentration using nanodrop showed significantly reduced levels in patients at 72 h of treatment compared to onset(P<0.01).However,RT-qPCR analysis showed a significant reduction at 24 h and 72 h of treatment compared to the disease onset(P<0.001).The sensitivity and specificity were relatively higher for RT-qPCR than nanodrop-based cfmtDNA quantification.Correlation analysis of both cf-mtDNA concentration as well as ND1 relative expression with National Institute of Health Stroke Scale score at baseline showed a positive trend.CONCLUSION In summary,quantitative estimation of highly pure cf-mtDNA provides a simple,highly sensitive and specific,non-invasive,and affordable approach for real-time monitoring and prognosticating AIS patients at onset and during treatment.
基金supported by the Science and Technical Committee of Shanghai Municipality of China,No.16QA1400900the Outstanding Youth Grant from Shanghai Municipal Commission of Health and Family Planning of China,No.XYQ2013107+1 种基金the China Postdoctoral Science Foundation,No.2016M592595the National Key Research and Development Program of China,No.2016YFA0203700
文摘Cerebral blood perfusion and cerebrovascular lesions are important factors that can affect the therapeutic efficacy of thrombolysis.At present,the majority of studies focus on assessing the accuracy of lesion location using imaging methods before treatment,with less attention to predictions of outcomes after thrombolysis.Thus,in the present study,we assessed the efficacy of combined computed tomography（CT） perfusion and CT angiography in predicting clinical outcomes after thrombolysis in ischemic stroke patients.The study included 52 patients who received both CT perfusion and CT angiography.Patients were grouped based on the following criteria to compare clinical outcomes：（1） thrombolytic and non-thrombolytic patients,（2） thrombolytic patients with CT angiography showing the presence or absence of a vascular stenosis,（3） thrombolytic patients with CT perfusion showing the presence or absence of hemodynamic mismatch,and（4） different CT angiography and CT perfusion results.Short-term outcome was assessed by the 24-hour National Institution of Health Stroke Scale score change.Long-term outcome was assessed by the 3-month modified Rankin Scale score.Of 52 ischemic stroke patients,29 were treated with thrombolysis and exhibited improved short-term outcomes compared with those without thrombolysis treatment（23 patients）.Patients with both vascular stenosis and blood flow mismatch（13 patients） exhibited the best short-term outcome,while there was no correlation of long-term outcome with CT angiography or CT perfusion findings.These data suggest that combined CT perfusion and CT angiography are useful for predicting short-term outcome,but not long-term outcome,after thrombolysis.
文摘目的探讨美国国立卫生研究院卒中量表(NIHSS)评分<6分的合并大血管闭塞的急性缺血性卒中(AIS-LVO)患者行血管内治疗(EVT)的预后影响因素。方法回顾性选取2021年1月至2023年1月在浙江省台州医院接受EVT的42例NIHSS评分<6分的AIS-LVO患者为研究对象。根据术后90 d改良Rankin量表(mRS)评分评估患者预后,比较预后良好组与预后不良组患者的临床资料,采用多因素logistic回归分析预后影响因素。结果所有患者均成功实现血管再通(100.0%),术中均未发生血栓逃逸、血管损伤、夹层、出血事件;术后发生24 h症状性颅内出血1例(2.4%),恶性脑水肿1例(2.4%)。随访90 d mRS评分显示预后良好33例,预后不良9例(未发生死亡病例)。预后良好组与预后不良组在年龄、术前舒张压、穿刺至再灌注时间等方面比较,差异均有统计学意义(均P<0.05)。穿刺至再灌注时间是影响NIHSS评分<6分的AIS-LVO患者行EVT预后的独立危险因素(OR=1.026,P=0.029)。结论NIHSS评分<6分的AIS-LVO患者行EVT可能是安全有效的,缩短穿刺至再灌注时间可能改善患者预后。
文摘目的通过对美国国立卫生研究院卒中量表（NIHSS）评分变化率的分析试图为脑梗死临床结局评价方法的选择提供一种新的思路与方法。方法本项研究采取前瞻性设计对来自10个临床研究中心急性期脑梗死住院患者的数据内容进行分析,筛选出入院当天NIHSS评分、发病90 d NIHSS评分和BI数据资料完整患者953例,将患者按入院时NIHSS评分分为3级：轻度（〈7分）、中度（7分-15分）、重度（〉15分）,以BI作为功能残疾的疗效判定＂金标准＂,发病90 d BI≥95分为预后良好、BI〈95分为预后不良的分界点将BI转换为二分类变量（残疾与否）,应用ROC曲线了解NIHSS的变化率对脑梗死患者发病90天功能残疾的判断价值。结果本研究发现NIHSS变化率预测脑梗死患者发病90 d功能残疾的AUC曲线下面积均〉0.70,轻度患者为0.76、中度患者为0.85,重度患者为0.97,与AUC曲线下面积=0.50进行比较,差异有统计学意义（P≤0.001）。预测脑梗死患者良好功能结局的最佳NIHSS变化率的截断值在轻度、中度、重度神经功能缺损的患者分别为70.8%、74.7%、84.9%;其灵敏度在三者分别为63.0%、81.8%、100.0%,特异度分别为78.1%、75.4%、94.3%。结论 NIHSS的变化率对脑梗死患者发病90 d功能残疾具有较好的预测能力,且这种预测能力随着神经功能缺损程度的增加而增大。
